For the past 10 years, Guardant Health has been defining the liquid biopsy space and has been a pioneer of sorts in the cancer detection market. The private company was one of the first in the space to go public and has secured a few FDA approvals to boot.

Guardant’s CEO and Co-founder Helmy Eltoukhy joins us for this episode of Let’s Talk Medtech to discuss the company’s past, present, and future. We also discuss the evolution of liquid biopsy and why the method holds so much promise for cancer detection.